Phenotypes Associated with This Genotype

Genotype
MGI:6693326

• Allelic Composition: Zdhhc2^em1Eko/Zdhhc2^em1Eko
• Genetic Background: C57BL/6-Zdhhc2^em1Eko

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

integument

decreased dendritic epidermal T cell number ( J:303593 )

• frequency and number of dendritic epidermal T cells are reduced in imiquimod-treated skin

decreased susceptibility to chemically induced skin inflammation ( J:303593 )

• mice show reduced susceptibility to imiquimod-induced psoriasis, with mice showing decreased thickness, scaling, erythema, and inflammatory response on the ear skin treated with imiquimod

• ears treated with imiquimod show decreased acanthosis and hyperkeratosis, with inhibited accumulation of immune cells

immune system

increased alpha-beta T cell number ( J:303593 )

• frequency and cell count of infiltrating alpha-beta T cells are increased in imiquimod-treated skin

increased gamma-delta T cell number ( J:303593 )

• frequency and cell count of infiltrating gamma-delta T cells are increased in imiquimod-treated skin

decreased leukocyte cell number ( J:303593 )

• mice treated with imiquimod show a decrease in the absolute number of white blood cells in treated skin

decreased plasmacytoid dendritic cell number ( J:303593 )

• mice treated with imiquimod show lower frequencies and absolute number of plasmacytoid dendritic cells in lesioned skin, spleen, and draining lymph nodes, however no differences in levels in the blood are seen

decreased dendritic epidermal T cell number ( J:303593 )

• frequency and number of dendritic epidermal T cells are reduced in imiquimod-treated skin

abnormal T cell activation ( J:303593 )

• expression of the T cell activation maker CD44 is decreased in alpha-beta T, gamma-delta T, and dendritic epidermal T cells of imiquimod-treated skin

abnormal cytokine level ( J:303593 )

• mice treated with imiquimod show decreased mRNA expression levels of pro-inflammatory cytokines, including IFN-alpha, TNF-alpha, IL-23, and IL-17a, in treated ear skin

abnormal interferon level ( J:303593 )

• expression of IFN-alpha in imiquimod-treated ear skin is reduced by as much as 23-fold

abnormal interleukin level ( J:303593 )

• expression of IL-23 and IL-17a in imiquimod-treated ear skin is reduced

abnormal tumor necrosis factor level ( J:303593 )

• expression of TNF-alpha in imiquimod-treated ear skin is reduced

abnormal plasmacytoid dendritic cell physiology ( J:303593 )

• expression of the plasmacytoid dendritic cell activation maker CD80 is decreased in imiquimod-treated lesioned skin

decreased susceptibility to chemically induced skin inflammation ( J:303593 )

• mice show reduced susceptibility to imiquimod-induced psoriasis, with mice showing decreased thickness, scaling, erythema, and inflammatory response on the ear skin treated with imiquimod

• ears treated with imiquimod show decreased acanthosis and hyperkeratosis, with inhibited accumulation of immune cells

homeostasis/metabolism

abnormal cytokine level ( J:303593 )

• mice treated with imiquimod show decreased mRNA expression levels of pro-inflammatory cytokines, including IFN-alpha, TNF-alpha, IL-23, and IL-17a, in treated ear skin

abnormal interferon level ( J:303593 )

• expression of IFN-alpha in imiquimod-treated ear skin is reduced by as much as 23-fold

abnormal interleukin level ( J:303593 )

• expression of IL-23 and IL-17a in imiquimod-treated ear skin is reduced

abnormal tumor necrosis factor level ( J:303593 )

• expression of TNF-alpha in imiquimod-treated ear skin is reduced

hematopoietic system

increased alpha-beta T cell number ( J:303593 )

• frequency and cell count of infiltrating alpha-beta T cells are increased in imiquimod-treated skin

increased gamma-delta T cell number ( J:303593 )

• frequency and cell count of infiltrating gamma-delta T cells are increased in imiquimod-treated skin

decreased leukocyte cell number ( J:303593 )

• mice treated with imiquimod show a decrease in the absolute number of white blood cells in treated skin

decreased plasmacytoid dendritic cell number ( J:303593 )

• mice treated with imiquimod show lower frequencies and absolute number of plasmacytoid dendritic cells in lesioned skin, spleen, and draining lymph nodes, however no differences in levels in the blood are seen

decreased dendritic epidermal T cell number ( J:303593 )

• frequency and number of dendritic epidermal T cells are reduced in imiquimod-treated skin

abnormal T cell activation ( J:303593 )

• expression of the T cell activation maker CD44 is decreased in alpha-beta T, gamma-delta T, and dendritic epidermal T cells of imiquimod-treated skin